A large study analyzed MEKi selumetinib, trametinib, PD0325901, MEK162, cobimetinib and refametinib in NF2-associated merlin-deficient schwannoma cells and mouse models and identified trametinib, PD0325901 and cobimetinib to be the most effective as well as uncovered resistance mechanisms [3]. The gene discussed is NF2; the disease is schwannoma.